• Skye Bioscience raised its authorized common stock to 300,000,000 shares from 100,000,000 in a Nevada charter amendment filed May 28, 2026.
• The change does not affect shares already issued or outstanding, expanding only the pool available for future issuance.
• Shareholders backed the increase at the May 26, 2026 annual meeting following a unanimous board recommendation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-039233), on May 29, 2026, and is solely responsible for the information contained therein.